# lung adenocarcinoma (LUAD) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 28524
- Completion tokens: 15229
- Reasoning tokens: 3402
- Total tokens: 43753
- API requests reported: 2
- Elapsed seconds: 75.219
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 1/5; original repeat 2; model vendor: MiniMax

---
<think>The user has provided a complex prognosis analysis task for lung adenocarcinoma (LUAD) with overall survival (OS) as the endpoint. Let me carefully analyze the input data.

**Data Quality Assessment:**
The statistical input is highly suspicious. Looking at the HR values:
- Many genes have HR values like 5.1847055e+21 (essentially infinite), which indicates these genes are likely:
  - Pseudogenes (many have names like RBMY1F, FAM9A, ATP5PBP2, RAP1BP2, etc.)
  - Unmapped ENSEMBL IDs
  - lncRNAs with RP11- prefixes
  - Y_RNA, RNU6-78P (small RNAs)
  - Many entries are TTTY4C (Y-linked), TEX13A, USP9YP3 - Y-chromosome/testis specific genes
  - Many are "UNMAPPED" entries
  
- P values of exactly 0 and FDR of exactly 0 are impossible - these are likely floored/saturated values
- TCP10L3 has HR=1.929e-22 (extremely protective, near-zero)
- HR of 5.18e+21 is essentially infinite, suggesting these genes were expressed in only one group (all events vs no events)

**Direction counts from ledger:** 96 risk-associated, 4 protective-associated
- Protective: TCP10L3 (HR~0), RBMXP1 (HR=0.21), CRNDE (HR=0.72), CMAHP (HR=0.71)

**Filtered candidates with reasonable HRs (likely non-artifactual):**
- PITX3 (HR=1.43)
- DKK1 (HR=1.48)
- LINC01312 (HR=1.36)
- LINC02178 (HR=1.30)
- VAX1 (HR=1.33)
- CTD-2066L21.1 (HR=1.27)
- CTD-2066L21.2 (HR=1.23)
- TLE1 (HR=1.48)
- LINC01910 (HR=1.31)
- LINC02323 (HR=1.37)
- CRNDE (HR=0.72)
- LINC02802 (HR=1.33)
- ITGB1-DT (HR=1.30)
- CREG2 (HR=1.33)
- LDLRAD3 (HR=1.42)
- KRT6A (HR=1.39)
- FUT4 (HR=1.40)
- RHOF (HR=1.40)
- RHCG (HR=1.29)
- CMAHP (HR=0.71)
- RGS20 (HR=1.35)

**Pathway/ontology batches:** GO Wnt signaling, Planar Cell Polarity, Cell Junction Disassembly; KEGG Mannose O-glycan, Wnt, Glycosphingolipid

**Recurrent modules from RAG:**
- molecular_function: CMAHP, DKK1, FAM9A, FUT4, KRT6A
- protein binding: DKK1, FAM9A, KRT6A, LDLRAD3, RBMXP1
- HIV elongation complex (likely coincidental annotation hits): CTD-2066L21.1/2, CTD-2151L9.2, CTD-2534I21.9
- RNA Pol II CTD phosphorylation
- snRNA genes transcription

**Network evidence:**
- RHOF: ACTN1, ARHGAP1 (actin cytoskeleton)
- FAM9A: ANOS1, ARSF
- VAX1: ASXL2
- FUT4: B3GNT3, B4GALT1 (glycosylation)
- LDLRAD3: APP

**Literature evidence:**
- ITGB1-DT as biomarker in LUAD (PMID 34906142)
- KRT6A biomarker in alopecia areata
- RhoF worse survival in AML (PMID 34405015)
- Ferritinophagy-related genes in NSCLC (PMID 40124684)

**Key biological themes:**
1. The majority of "top hits" are likely technical artifacts (pseudogenes, Y-linked, lncRNAs with HR=∞) suggesting very low expression events causing complete separation
2. Real biological signal: Wnt signaling (DKK1 is a key Wnt antagonist, also VAX1 - associated with Wnt/PCP), cell adhesion (ITGB1-DT linked to integrin β1), cytoskeleton (RHOF), glycosylation (FUT4), keratin/epithelial-mesenchymal (KRT6A)
3. Several homeobox transcription factors: PITX3, VAX1, TLE1 - developmental transcription factors
4. G-protein signaling: RGS20, RHOF

**Programs to consider:**
1. **Wnt signaling dysregulation** - DKK1 is a major Wnt antagonist (risk), with the GO batch flagging Wnt regulation, PCP pathway, cell junction disassembly
2. **Cell adhesion/integrin-EMT** - ITGB1-DT, RHOF (actin), KRT6A
3. **Glycosylation/surface antigen remodeling** - FUT4 (fucosyltransferase)
4. **Developmental transcription factor reactivation** - PITX3, VAX1, TLE1 (Groucho/TLE family repressors)
5. **G-protein/cytoskeletal signaling** - RGS20, RHOF, RHCG

**Key genes (most biologically interpretable, not artifacts):**
1. DKK1 (Wnt antagonist, risk)
2. ITGB1-DT (integrin β1 divergent transcript, risk) - has literature in LUAD
3. PITX3 (transcription factor, risk)
4. VAX1 (homeobox, risk) - linked to Wnt/PCP via RAG network
5. TLE1 (Groucho repressor, risk)
6. RHOF (Rho GTPase, risk) - has AML survival literature
7. FUT4 (fucosyltransferase, risk) - glycosylation
8. KRT6A (keratin, risk)
9. CREG2 (cellular repressor of E1A-stimulated genes, risk)
10. RGS20 (G-protein signaling regulator, risk)

Protective:
- CRNDE (HR=0.72) - known lncRNA, complex roles
- CMAHP (HR=0.71) - CMP-N-acetylneuraminic acid hydroxylase
- RBMXP1 - pseudogene
- TCP10L3 - extreme HR (likely artifact)

**Validation priorities:**
1. DKK1/Wnt mechanism in LUAD
2. ITGB1-DT as biomarker (literature support exists)
3. Glycosylation remodeling via FUT4
4. Cytoskeletal/integrin signaling (RHOF, ITGB1-DT, KRT6A)
5. Confounding/composition check (why are so many pseudogenes and Y-linked transcripts risk-associated? Likely technical)

**Limitations:**
- Data quality concerns: 73/100 genes have HR = 5.18e+21 (effectively infinite), likely artifacts of low expression/perfect separation in single subgroup
- Many "risk" genes are pseudogenes, lincRNAs without functional annotation, Y-linked/testis-specific transcripts
- No independent cohort validation
- HR of 5.18e+21 is mathematically meaningless for biology

Let me structure the answer following the user's requirements.</think>

## Data-Quality Warning (Read First)

Before any biological interpretation, several features of this prognostic table indicate that the bulk of the signal is **technical rather than biological**, and any interpretation must be calibrated accordingly.

- **Saturation of effect size:** 73/100 genes carry HR = 5.1847×10²¹, and the remaining 27 have HR values that span 22 orders of magnitude (1.9×10⁻²² to 1.9×10⁹). HRs of this magnitude are mathematically equivalent to *infinite* hazard and almost always reflect **complete separation** — the gene is detected in essentially every short-surviving patient and in essentially no long-surviving patient (or vice versa).
- **Saturated P values:** Every one of the top 73 rows has P = 0 and FDR = 0. These are not true zeros; they are values that fell below the floating-point underflow threshold of the survival model. They cannot be ranked against each other.
- **Locus composition of the saturated set:** the saturated list is dominated by (i) Y-linked / testis-restricted transcripts (RBMY1F, FAM9A, TTTY4C, USP9YP3, TEX13A, CDY10P, TCP10L3, RBMY2AP, VENTXP7, AMMECR1LP1), (ii) processed pseudogenes (ATP5PBP2, RAP1BP2, RNY1P3, MTND1P1, ETFRF1P1, HMGN2P39, ATG4AP1, DRAXINP1, DIMT1P1, RBMXP1), (iii) small-RNA / snRNA / Y_RNA annotations (RNU6-78P, RNU7-99P, Y_RNA, H2AZP7), (iv) UNMAPPED Ensembl contigs and uncharacterized lincRNAs. None of these have a mechanistic precedent as LUAD drivers, and several are expected to be **expressed only in male germ cells** — meaning their "prognostic" HR is more plausibly driven by sex composition of the survival tail or by low-count dropout than by tumor biology.
- **No external-cohort replication is available.** The adjudication block explicitly states `INDEPENDENT COHORT VALIDATION: status=not_available`. Pathway / interaction / literature records used below are contextual, not statistical, replication.
- **Direction conflict note from the ledger:** the Y_RNA entry carries 163 input rows that disagree on direction, so even within this artifact-prone set there is internal inconsistency.

**Practical implication:** the only rows whose HRs and P values are individually interpretable are the ~27 genes with finite HRs and meaningful P/FDR (DKK1 through RGS20 in the supplied table). The interpretation below therefore concentrates on this finite-HR subset, treats the saturated set as a single technical artifact signal, and explicitly flags when conclusions are extrapolated.

---

## 1. Overall Biological Interpretation

Within the interpretable subset, the prognostic signature in this LUAD cohort converges on three coherent biological themes:

1. **Reactivation of developmental / morphogenetic transcription programs with Wnt-pathway bias.** The risk-associated set includes a homeobox transcription factor (PITX3), a Wnt-pathway-relevant homeobox gene (VAX1, present in the STRING/Ensembl network linked to ASXL2 and to the GO Planar Cell Polarity Pathway batch), and a Groucho/TLE-family transcriptional co-repressor (TLE1). DKK1 — the most statistically robust protein-coding risk gene in the table — is a canonical secreted Wnt antagonist whose overexpression in LUAD has repeatedly been tied to poor outcome, EMT-like states, and immune-cold microenvironments. The Wnt / Planar Cell Polarity / cell-junction-disassembly GO batch retrieved by RAG is biologically concordant with this.

2. **Cell–matrix, cytoskeletal, and integrin-axis remodeling.** ITGB1-DT (a divergent transcript linked to ITGB1/integrin-β1) is risk-associated and is the only gene in this list with prior peer-reviewed support in LUAD specifically (PMID 34906142: "ITGB1-DT/ARNTL2 axis may be a novel biomarker in lung adenocarcinoma"). RHOF (a Rho-family GTPase acting on actin filaments) is risk-associated and has prior worse-survival evidence in a non-LUAD solid tumor (PMID 34405015, AML). KRT6A (a keratin-6 isoform often upregulated during epithelial stress / squamous-program reactivation) and CREG2 (a glycoprotein-linked repressor of E1A-stimulated genes) further support an adhesion / cytoskeletal / epithelial-state program.

3. **Glycosylation and surface-antigen remodeling.** FUT4 (α-1,3-fucosyltransferase IV) is risk-associated; the KEGG batch explicitly flags mannose-type O-glycan biosynthesis and glycosphingolipid biosynthesis. FUT4 has direct STRING links to B3GNT3 and B4GALT1 in the network block, supporting a real glycosyltransferase module rather than annotation noise.

Counterbalancing these are two protective protein-coding candidates: **CRNDE** (a well-known lncRNA with complex, context-dependent roles) and **CMAHP** (a CMP-N-acetylneuraminic acid hydroxylase pseudogene whose status in LUAD is poorly characterized). Their protection should be treated cautiously because pseudogene-derived signal is vulnerable to the same dropout / sex-composition confound that afflicts the saturated set.

The remaining ~73 saturated rows are best interpreted as a **single composite technical signal** — extremely sparse, low-expression, lineage-restricted, or unmapped features that achieved complete separation in one tail of the survival distribution. They are not a coherent biological program.

---

## 2. Core Biological Programs

### Program A — Wnt-pathway reactivation with DKK1 as the lead risk gene
- **Direction:** risk-associated (HR > 1).
- **Major supporting genes:** DKK1 (HR = 1.475, FDR = 3.55×10⁻⁷); VAX1 (HR = 1.335, FDR = 9.25×10⁻⁶); PITX3 (HR = 1.429, FDR = 3.49×10⁻¹¹); TLE1 (HR = 1.484, FDR = 2.46×10⁻⁵).
- **Standardized annotation:** GO Regulation of Wnt signaling pathway (GO:0030111), Planar Cell Polarity Pathway (GO:2000096), Cell Junction Disassembly (GO:0150146); KEGG Wnt signaling pathway.
- **Why these genes collectively indicate this program:** DKK1 is the canonical secreted Wnt antagonist and is itself a clinical/translational node in NSCLC; VAX1 is a homeobox gene whose homologs interact with the non-canonical Wnt/PCP cascade (GO:2000096 is among the retrieved ontology hits); PITX3 and TLE1 are transcriptional regulators with documented cross-talk to Wnt/β-catenin and TCF/LEF programs in epithelial development. Their joint risk direction is consistent with a reactivated morphogenetic program.
- **Strength / limitations:** DKK1 and TLE1 are the only entries with HR P values small enough to be individually meaningful (P ≤ 4×10⁻⁸), and DKK1 has independent LUAD literature support. The link for PITX3 and VAX1 to Wnt in LUAD specifically is largely inferred from ontology co-membership rather than direct LUAD statistics — treat as supported hypothesis, not established evidence. None of these genes has an independent-cohort replication statistic in the supplied evidence pack.

### Program B — Integrin / cytoskeletal / epithelial-state remodeling
- **Direction:** risk-associated.
- **Major supporting genes:** ITGB1-DT (HR = 1.302, FDR = 1.48×10⁻⁴); RHOF (HR = 1.403, FDR = 4.00×10⁻⁴); KRT6A (HR = 1.390, FDR = 2.78×10⁻⁴); CREG2 (HR = 1.332, FDR = 1.63×10⁻⁴).
- **Standardized annotation:** GO Cell Junction Disassembly (GO:0150146); Reactome / KEGG modules related to actin cytoskeleton, Rho-GTPase signaling, focal adhesion.
- **Why these genes collectively indicate this program:** ITGB1-DT is in cis with ITGB1 (integrin β1), a central ECM receptor; RHOF directly remodels the actin cytoskeleton and has STRING links to ACTN1 and ARHGAP1; KRT6A is a stress / wound-response keratin that is often co-expressed with squamous or EMT-like transcriptional programs; CREG2 is implicated in glycoprotein-mediated adhesion signaling. The shared direction (all risk) supports a coherent pro-invasive state.
- **Strength / limitations:** ITGB1-DT is the strongest literature-supported LUAD candidate in the table (PMID 34906142; also PMID 37690573 for breast cancer). RHOF has worse-survival evidence only in AML (PMID 34405015), not in LUAD. Network links are STRING-only and represent protein-protein interaction evidence (not co-expression or pathway co-membership).

### Program C — Glycosylation / surface-antigen remodeling
- **Direction:** risk-associated.
- **Major supporting genes:** FUT4 (HR = 1.403, FDR = 2.93×10⁻⁴); CMAHP (HR = 0.706, FDR = 5.77×10⁻⁴, protective); RHCG (HR = 1.290, FDR = 4.73×10⁻⁴, ammonium / ammonium-transport-linked, included because it is one of the molecular-function ontology recurrences).
- **Standardized annotation:** KEGG Mannose type O-glycan biosynthesis; KEGG Glycosphingolipid biosynthesis; GO molecular_function glycosyltransferase activity.
- **Why these genes collectively indicate this program:** FUT4 (α-1,3-fucosyltransferase) drives Lewis-antigen and selectin-ligand biosynthesis relevant to immune-cell trafficking and tumor-cell adhesion. CMAHP — a pseudogene of the sialic-acid hydroxylase CMAH — sits directly in the sialic-acid / glycosylation pathway; its protective direction is biologically plausible (loss of a hydroxylase-competent paralog could shift the sialylation balance).
- **Strength / limitations:** This is the weakest of the three programs in terms of independent LUAD literature; the KEGG hits come from a small selected set and may reflect recurrence within the uploaded genes rather than pathway enrichment. Label as **exploratory hypothesis**.

### Program D — Y-linked / testis-restricted and pseudogene saturation (technical composite)
- **Direction:** nominally risk-associated, but biologically uninterpretable.
- **Major supporting entries:** RBMY1F, FAM9A, TTTY4C, USP9YP3, TEX13A, CDY10P, TCP10L3, RBMY2AP, AMMECR1LP1, RNY1P3, MTND1P1, ATP5PBP2, RAP1BP2, DRAXINP1, ETFRF1P1, HMGN2P39, ATG4AP1, DIMT1P1, RBMXP1, the CTD-/RP11-/AF-/LOC-/UNMAPPED_ENSEMBL_* lincRNA cloud, and small-RNA / Y_RNA features.
- **Standardized annotation:** no coherent GO/KEGG/Reactome module ties them together beyond the molecular_function "protein binding" bucket (which is essentially uninformative).
- **Why these are best treated as one program:** their HRs have saturated, their P values are zero, and their genomic identity (Y-linked, processed pseudogene, small ncRNA, unmapped contig) collectively indicates a **dropout / count-extremes artifact** rather than a coordinated transcriptional program. Underlying mechanism is most plausibly: (a) very low expression in tumor RNA-seq with sporadic detection in a small subset of patients who happen to fall in the short-survival tail; (b) confounding by patient sex if the cohort is mixed, since most Y-linked / testis transcripts will be male-specific; (c) batch-specific mappability issues for unmapped contigs.
- **Strength / limitations:** Strongly *negatively* informative — these rows should be filtered or flagged before any downstream modeling. Label as **confounding / composition signal**, not a biological program.

### Program E — Protective lncRNA / pseudogene signal
- **Direction:** protective (HR < 1).
- **Major supporting entries:** CRNDE (HR = 0.716, FDR = 1.03×10⁻⁴); CMAHP (HR = 0.706, FDR = 5.77×10⁻⁴); RBMXP1 (HR = 0.212, FDR = 1.60×10⁻¹⁷, protective direction-conflict-clean within its row); TCP10L3 (HR = 1.93×10⁻²², saturated — protective).
- **Why these are presented as a separate program rather than folded into D:** protection is the opposite of the dominant risk direction, but two of the three genes with finite HR (CRNDE, CMAHP) sit in the glycosylation / chromatin-neighborhood and have plausible but unconfirmed protective mechanisms in LUAD. RBMXP1 is an RBMX-processed pseudogene (RBMX itself is an RNA-binding chromatin regulator), and its protective signal is interpretable but vulnerable to the same dropout confound that affects Program D.
- **Strength / limitations:** Label as **exploratory hypothesis**. No independent cohort validation.

---

## 3. Key Genes / Interaction Modules

Only candidates with finite HR, individually interpretable P and FDR, and non-trivial external evidence are listed; the saturated set is summarized as a single artifact module.

1. **DKK1** — risk (HR 1.475, FDR 3.55×10⁻⁷). Canonical secreted Wnt antagonist; in NSCLC its high expression has been tied to EMT, bone metastasis, and immune-cold phenotypes. *Relationship to other candidates:* DKK1 is a pathway co-member with Wnt/β-catenin and non-canonical Wnt programs in which VAX1, TLE1, and PITX3 participate (pathway co-membership, not direct physical interaction).
2. **ITGB1-DT** — risk (HR 1.302, FDR 1.48×10⁻⁴). Divergent transcript linked to ITGB1. Has explicit LUAD biomarker literature (PMID 34906142). *Relationship:* cis-regulatory / co-expression candidate with ITGB1; in the literature it forms an axis with ARNTL2. The interaction is best characterized as a regulatory/co-expression relationship, not a confirmed direct physical interaction.
3. **PITX3** — risk (HR 1.429, FDR 3.49×10⁻¹¹, the strongest P value among the finite-HR set). Paired-like homeodomain transcription factor; developmental. *Relationship:* co-expression / pathway co-membership with Wnt/PCP and homeobox programs. No direct physical interaction is supported by the supplied STRING/IntAct/OmniPath evidence for PITX3 with other selected candidates.
4. **VAX1** — risk (HR 1.335, FDR 9.25×10⁻⁶). Ventral anterior homeobox 1; a Wnt/PCP-relevant homeobox gene. *Relationship:* STRING network link to ASXL2 (a chromatin / polycomb-associated factor). This is a STRING-inferred protein-protein interaction (high-throughput / computational), not a curated direct physical interaction in IntAct.
5. **TLE1** — risk (HR 1.484, FDR 2.46×10⁻⁵). Groucho/TLE transcriptional co-repressor; known Wnt/β-catenin modulator in epithelial contexts. *Relationship:* pathway co-membership with Wnt programs; no direct PPI to other selected candidates in the supplied evidence.
6. **RHOF** — risk (HR 1.403, FDR 4.00×10⁻⁴). Rho-family GTPase, actin cytoskeleton. *Relationship:* STRING-confirmed PPIs with ACTN1 and ARHGAP1 (these partners are **not** themselves in the selected set). Direct physical interaction supported only by STRING scoring; in the context of the selected set the relationship is pathway co-membership / cytoskeletal module co-membership rather than direct physical binding among selected genes.
7. **FUT4** — risk (HR 1.403, FDR 2.93×10⁻⁴). α-1,3-fucosyltransferase. *Relationship:* STRING PPIs with B3GNT3 and B4GALT1 (glycosyltransferases not in the selected set); pathway co-membership within the KEGG glycosphingolipid / mannose-O-glycan modules.
8. **KRT6A** — risk (HR 1.390, FDR 2.78×10⁻⁴). Stress / wound-response keratin. *Relationship:* GO molecular_function "protein binding" co-membership with DKK1, FAM9A, LDLRAD3, RBMXP1 — this is ontology co-membership, not a direct physical interaction. KRT6A is most plausibly interpreted as an EMT / epithelial-state marker.
9. **CRNDE** — protective (HR 0.716, FDR 1.03×10⁻⁴). lncRNA with reported roles in chromatin regulation and metabolic reprogramming across cancers. *Relationship:* literature co-occurrence and (in some studies) co-expression with Wnt/IGF pathways — but in the supplied evidence pack there is no direct PPI or curated regulatory link between CRNDE and the other selected candidates.
10. **Saturated Y-linked / pseudogene / unmapped artifact module** (representative: RBMY1F, FAM9A, TTTY4C, USP9YP3, ATP5PBP2, RAP1BP2, RNY1P3, TCP10L3, plus the UNMAPPED_ENSEMBL_* and RP11-* / AF24* lincRNA cluster). Treat as one composite signal, not as individual genes.

---

## 4. Validation Priorities

### Priority 1 — DKK1 as a mechanistic / biomarker node in LUAD (Mechanistic hypothesis + Biomarker)
- **Why prioritized:** DKK1 is the protein-coding risk gene with both the strongest finite HR statistics and the strongest external LUAD literature.
- **Dataset evidence:** HR 1.475, FDR 3.55×10⁻⁷, P 4.27×10⁻¹⁰, direction concordant with multiple risk-associated Wnt/PCP co-members.
- **External support:** independent published evidence of DKK1 overexpression in NSCLC with prognostic and immune-microenvironment consequences (not in the supplied evidence pack as an actual independent-cohort statistic).
- **Next step:** validate DKK1 protein levels (IHC) in a non-overlapping LUAD cohort with annotated OS; orthogonal confirmation of any DKK1-centered risk score.
- **Status:** **Supported hypothesis** for biomarker status; **exploratory hypothesis** for the specific causal mechanism.

### Priority 2 — ITGB1-DT / integrin-β1 axis as a LUAD biomarker (Biomarker)
- **Why prioritized:** ITGB1-DT is the only candidate with explicit published LUAD biomarker work (PMID 34906142), giving an external anchor to test.
- **Dataset evidence:** HR 1.302, FDR 1.48×10⁻⁴, direction concordant with cytoskeletal / EMT co-members (RHOF, KRT6A, CREG2).
- **External support:** PMID 34906142 (ITGB1-DT/ARNTL2 axis in LUAD); PMID 37690573 (ITGB1-DT in breast cancer).
- **Next step:** qPCR validation of ITGB1-DT in an independent FFPE LUAD cohort with OS, plus exploration of ARNTL2 as a co-regulated partner.
- **Status:** **Supported hypothesis** (literature-anchored) for biomarker status; **exploratory** for the ARNTL2 axis in this specific cohort.

### Priority 3 — Glycosylation remodeling (FUT4 ± CMAHP) (Mechanistic hypothesis)
- **Why prioritized:** FUT4 has finite, robust statistics; CMAHP, while protective, sits directly in sialic-acid biology and gives the program internal directionality. Together they map onto a KEGG module (mannose-type O-glycan, glycosphingolipid biosynthesis) that is biologically plausible in LUAD but underexplored.
- **Dataset evidence:** FUT4 HR 1.403 / FDR 2.93×10⁻⁴ (risk); CMAHP HR 0.706 / FDR 5.77×10⁻⁴ (protective); reciprocal directions are biologically interpretable.
- **External support:** STRING PPIs between FUT4 and B3GNT3 / B4GALT1 (interaction network evidence, not LUAD-specific clinical evidence). No independent-cohort LUAD replication statistic supplied.
- **Next step:** targeted mass-spec or lectin-panel glycomics on a small validation cohort to test whether FUT4-high / CMAHP-low tumors show a defined glycosignature.
- **Status:** **Exploratory hypothesis**.

### Priority 4 — Cytoskeletal / Rho-driven program (RHOF, KRT6A, CREG2) (Mechanistic / Therapeutic target)
- **Why prioritized:** RHOF is a druggable GTPase axis and has external worse-survival evidence in another hematologic malignancy (PMID 34405015, AML). The cluster is internally coherent with ITGB1-DT.
- **Dataset evidence:** RHOF HR 1.403 / FDR 4.00×10⁻⁴; KRT6A HR 1.390 / FDR 2.78×10⁻⁴; CREG2 HR 1.332 / FDR 1.63×10⁻⁴.
- **External support:** RHOF AML literature; KRT6A multi-omics work in alopecia areata (Europe PMC 42216026) is not directly relevant to LUAD outcome. **Important caveat:** the existence of any drug screen hits against RHOF (CHEMBL records in the evidence pack) does **not** by itself establish RHOF as an effective LUAD therapeutic target.
- **Next step:** IHC / RNA validation in independent cohorts; functional knock-down of RHOF in LUAD cell lines to test invasion / survival phenotypes.
- **Status:** **Exploratory hypothesis** for therapeutic target; **supported hypothesis** for prognostic association.

### Priority 5 — Confounding / composition check on the saturated Y-linked + pseudogene + unmapped set (Confounding or composition check)
- **Why prioritized:** Without this check, any downstream model risks attributing a sex / dropout / mappability artifact to "tumor biology." This is the single most important methodological priority for this dataset.
- **Dataset evidence:** 73/100 genes have HR = 5.18×10²¹, dominated by Y-linked, testis-restricted, processed-pseudogene, and UNMAPPED_ENSEMBL_* loci; Y_RNA itself shows a direction conflict across 163 input rows.
- **External support:** general knowledge that Y-linked transcripts are male-specific and that processed pseudogenes are typically expressed at very low levels with sporadic detection — both are well-documented dropout confounders in RNA-seq survival models. (No specific database claim is being made beyond that background expectation.)
- **Next step:** stratify Cox models by patient sex; recompute HRs after filtering low-expression features; cross-reference UNMAPPED_ENSEMBL_* contigs against current GENCODE / Ensembl builds to resolve their genomic identity before any biological claim is made.
- **Status:** **Established evidence** that such artifacts are common in RNA-seq survival modeling; this specific contribution in *this* cohort is **exploratory** until the composition check is performed.

---

## 5. Evidence-Grounding Summary

| Claim | Evidence classes supporting it | Independent? |
|---|---|---|
| DKK1 is a LUAD risk gene | Direct dataset (HR 1.475, FDR 3.55×10⁻⁷) + GO/KEGG Wnt pathway batch + prior NSCLC literature | GO/KEGG and literature may share underlying Wnt-pathway review papers; treat as partially overlapping |
| ITGB1-DT is a LUAD risk biomarker | Direct dataset (HR 1.302) + PMID 34906142 (direct LUAD biomarker study) + PMID 37690573 (breast cancer, indirect) | The LUAD PMID is a distinct study; the breast cancer PMID is an independent cohort but a different disease |
| RHOF predicts worse survival | Direct dataset (HR 1.403) + STRING PPIs (ACTN1, ARHGAP1) + PMID 34405015 (AML, different disease) | The AML PMID is independent evidence but in a different indication — does not replicate LUAD |
| FUT4 / CMAHP form a glycosylation module | Direct dataset (HRs opposite in direction, both finite) + KEGG mannose-O-glycan / glycosphingolipid batch + STRING FUT4-B3GNT3 / FUT4-B4GALT1 | KEGG and STRING may share underlying glycosyltransferase annotation pipelines — treat as partially overlapping |
| VAX1 / PITX3 / TLE1 form a Wnt / developmental TF program | Direct dataset (all risk, finite HRs, strong P values) + GO Wnt regulation / PCP pathway batch + STRING VAX1-ASXL2 link | GO and STRING are largely independent databases, but TLE1/PITX3 links to Wnt in LUAD specifically are not externally validated |
| The saturated Y-linked / pseudogene cluster reflects a technical artifact | Direct dataset (HR saturation, P = 0, FDR = 0, genomic identity of the entries) + general knowledge of RNA-seq dropout + Y_RNA direction conflict | The general artifact expectation is well-established; the magnitude of its contribution to *this* specific dataset is exploratory until the composition check is done |

**No independent-cohort replication statistic is present in the evidence pack**, so none of the prognostic associations above should be presented as having been externally replicated.

---

## 6. Limitations and Alternative Explanations

1. **Saturation / complete-separation artifact (Program D).** The HR = 5.18×10²¹ rows reflect a numerical pathology, not biology. Any aggregate score that weights these rows by their HR will be dominated by them. Filtering on minimum expression (e.g., median TPM ≥ a small threshold) and re-fitting Cox models is the minimum check.

2. **Sex and lineage composition.** Y-linked transcripts (RBMY1F, FAM9A, USP9YP3, TTTY4C, TEX13A, USP9YP3, CDY10P, TCP10L3, RBMY2AP, AMMECR1LP1, VENTXP7) and many testis-restricted processed pseudogenes will be detected essentially only in male patients. If the survival tail is sex-imbalanced — for instance, because of differential smoking exposure or histology-by-sex interactions in LUAD — the apparent "risk" signal is partly or wholly a sex-composition artifact. Stratifying the Cox model by sex, or restricting to one sex, is the standard disambiguation.

3. **Tumor purity and stromal / immune admixture.** DKK1 is secreted and is also a stromal / immune-modulator; FUT4 acts on tumor-cell surface glycans that interact with infiltrating immune cells. Without a tumor-purity adjustment (ESTIMATE / ABSOLUTE / CPE) or deconvolution, the HR may partly reflect microenvironment composition rather than tumor-cell-intrinsic expression. This is especially relevant for any future biomarker translation.

4. **Batch / platform effects and read-mappability.** The UNMAPPED_ENSEMBL_* contigs and several RP11-* / AF* lincRNAs may reflect genomic regions with library- or aligner-specific mappability. A platform effect or reference-build mismatch can produce complete-separation HRs in a subset of samples purely from alignment differences. Re-mapping to the current GENCODE build with a splice-aware aligner and re-quantifying is the appropriate control.

5. **Association-vs-causation and small-subgroup effects.** All HRs are observational. Several finite-HR genes (PITX3, DKK1, TLE1) could be passengers of an upstream driver (e.g., a transcriptionally defined LUAD subtype or a co-occurring mutation). The fact that they co-vary with each other does not establish a causal chain. Functional perturbation (CRISPR knock-down, overexpression) in LUAD cell lines and ideally in patient-derived organoids is the standard disambiguation.

The dominant takeaway: only DKK1, ITGB1-DT, PITX3, TLE1, VAX1, RHOF, KRT6A, FUT4, CREG2, RHCG, CMAHP, and CRNDE have individually interpretable prognostic statistics in this table. The remaining ~88 rows should be regarded as a single artifact-dominated signal until a sex-stratified, low-expression-filtered re-analysis is performed, and no causal mechanism should be attributed to them on the basis of this table alone.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=88, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
